ArticleJournal for immunotherapy of cancer2023

Runx3-overexpression cooperates with ex vivo AKT inhibition to generate receptor-engineered T cells with better persistence, tumor-residency, and antitumor ability.

Jianghui Tang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.